Dabur’s Q3FY21 results were in line with our estimate. Domestic FMCG volumes increased by 18.1% YoY – second consecutive quarter of double digit volume growth. Growth in the domestic market was driven by health care (+28.1%) and HPC (+15.9%) business. Healthcare contribution grew from 40% in Q3FY20 to 44% in Q3FY21 led by market share gains in chyawanprash and honey. The healthcare category is expected to grow faster post Covid with new launches.
OutlookWe have broadly maintained our FY21/22/23E EPS estimates at Rs 9.4/9.8/10.8. We value the stock at 50x FY23E EPS to arrive at a TP of Rs 540. Considering rich valuations, we maintain Reduce; buy on dips.
For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.